Valspodar is a second-generation, non-immunosuppressive inhibitor of P-glycoprotein (Pgp) that reverses multidrug resistance by blocking drug efflux. It enhances the intracellular accumulation of chemotherapeutics like mitoxantrone, restoring drug sensitivity in resistant cancer cells.